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arts, hypogammaglobulinemia, infections, and
myelokathexis (WHIM) syndrome is a rare im-
munodeficiency disorder characterized by warts,
hypogammaglobulinemia, infections, and abnormal reten-
tion of mature neutrophils in the bone marrow (myeloka-
thexis).1,2 This neutropenia, which is associated with
a B and T lymphopenia and hypogammaglobulinemia, re-
sults in an increased risk for bacterial infections. Patients
with WHIM syndrome present major and selective suscepti-
bility to human papillomavirus that may manifest as cutane-
ous warts and genital dysplasia and cancer. The real
prevalence of the disease is unknown but 40 cases have
been reported.3 Autosomal dominant heterozygous muta-
tions of the gene encoding the CXC chemokine receptor 4
(CXCR4) have been associated with the syndrome4 and
lead to a gain of CXCR4 function.5,6 CXCR4 is a G pro-
tein–coupled receptor with a unique ligand, CXCL12 (previ-
ously named SDF-1).7,8 This signaling axis orchestrates
leukocyte trafficking and is involved in the regulation of
bone marrow homeostasis, hematopoiesis, and organogene-
sis.9-11 Notably, besides hematopoietic and central nervous
system defects, mice deficient for CXCR4 or CXCL12 exhibit
cardiac defects, indicating a role for this axis in ventricular
septum formation.12,13
Tetralogy of Fallot (TOF) is a congenital heart disease
characterized by: (1) pulmonary outflow tract obstruction;
(2) ventricular septal defect; (3) overriding aortic root;
and (4) right ventricular hypertrophy. The first 3 features
are the result of abnormalities occurring during embryo-
genesis, and the fourth one is the consequence of the
obstruction to pulmonary blood flow. The etiology is mul-
tifactorial. To date, some genetic alterations, the most
frequent being represented by microdeletions of chromo-
some 22, have been associated with TOF but pathogenesis
still remains unclear. The incidence is of 3 of every 10
000 live births, which represents approximately 10% of all
congenital defects.14-16TOF Tetralogy of Fallot
WHIM Warts, hypogammaglobulinemia, infections, and
myelokathexisResults
We report the cases of 3 patients with WHIM syndrome who
are affected by TOF (Figure). Taking into consideration the
relatively poor prevalence of the two disorders, in the present
report we show that patients with WHIM syndrome display
an increased risk to develop TOF.
The first patient is a 19-year-old man with a history of
WHIM syndrome identified at age 2.5 years, manifesting as
severe neutropenia and recurrent pneumonias, resulting in
bronchiectases (Table). There was no evidence of
hypogammaglobulinemia and warts. The bone marrow
analysis showed myeloid hypercellularity with the presence
of mature neutrophils. These hematologic and clinical
findings led to the suspicion of WHIM syndrome and
thereby to CXCR4 gene sequencing that revealed S338X
mutation. The congenital heart disease was suspected at
birth and was characterized by the anatomic variant of TOF
associated with pulmonary atresia and with anomalies in
branch pulmonary arteries. Of note, the patient presented
with agenesis of the left-hand fingers with homolateral
hypoplasia of the radius. The patient has been maintained
on daily subcutaneously administered granulocyte-colony
stimulating factor therapy since 2 years of age.
In the second case, the patient had TOF associated with
the presence of patent ductus arteriosus documented at birth;
the heart disease was surgically corrected at the age of 2
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Figure. Pedigree trees of the three WHIM patients, who are
affected by TOF.
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 161, No. 4had recurrent respiratory infections since early childhood.
Severe neutropenia was discovered at age of 2 years, and on
that occasion, an analysis of the bone marrow revealed
myelokathexis with mature neutrophils presenting
morphologic abnormalities consistent with apoptosis.
Granulocyte-colony stimulating factor therapy was started
at 5 years of age to maintain circulating neutrophil count
in the normal range. Because of the occurrence of repeated
pneumonia episodes, she has been maintained on antibiotic
prophylaxis. In the following years, the observation of
hypogammaglobulinemia suggested WHIM syndrome andTable. Features of WHIM syndrome in reported patients
Feature Patient 1
Mutation (CXCR4) S338X
Age at molecular diagnosis 19 y
Clinical manifestations at onset TOF
Neutropenia (age at onset) + (2.5 y)
Myelokathexis +
Hypogammaglobulinemia (age at onset) 
Recurrent infections Pneumonia
Warts 
Pulmonary outflow obstruction Pulmonary valve agenesis
Overriding aorta +
Ventricular septal defect +
Right ventricular hypertrophy +
Age at surgical correction 1 y
Medical treatment G-CSF; antibiotic prophylaxis
G-CSF, Granulocyte-colony stimulating factor; IVIG, Intravenous immunoglobulins.
*One episode without relapse.
764genetic confirmation of the diagnosis was obtained at age 5
by detection of the R334X mutation in the CXCR4 gene. In
the following years, the patient has developed a plantar wart.
The third patient is 7 years old and presented shortly after
birth with a heart murmur that led to the discovery of
a TOF characterized by ventricular septal defect, overriding
aorta, and pulmonary infundibular stenosis. The congenital
heart disease was surgically corrected in the first months of
life. Neutropenia, lymphopenia, and hypogammaglobulin-
emia were present since infancy, and the analysis of bonemar-
row showedmyelokathexis. Three other familymembers have
had neutropenia and recurrent infections, but none of them
had a congenital heart defect. The genetic analysis of CXCR4
revealed the same mutation (S338X) in the 4 subjects. The
child underwent treatment with intravenous immunoglobu-
lins, obtaining a satisfactory control of infectious episodes.
Discussion
Although TOF is the most common form of cyanotic con-
genital heart disease, its occurrence in 3 unrelated patients
with WHIM syndrome is much higher than expected; the
normal occurrence in the general population is 3 of every
10 000 live births. Because of the low number of patients
whom we have observed, we cannot draw a correlation be-
tween the development of the heart defect with a specific mu-
tation. The detection of the same mutation (S338X) in
a family with 4 members affected by WHIM syndrome
with only 1 showing TOF rules out the hypothesis that the
heterozygous gain-of-function mutation of CXCR4 directly
leads to the development of the cardiac defect. Instead, our
observations suggest that the WHIM syndrome–associated
CXCR4 truncating mutation might increase the risk that
this combination of cardiac defects may develop during the
formation of the fetal heart. Beyond a role for CXCL12 and
CXCR4 in heart, nervous system, and blood vessel develop-
ment,17 studies show that CXCR7, the recently described sec-
ond receptor for CXCL12,18,19 has also a role in fetalPatient 2 Patient 3
R334X S338X
5 y Birth (neutropenia and affected father)
TOF TOF; neutropenia
+ (2 y) + (20 d)
+ +
+ (5 y) + Not really assessable as early IVIG at
the onset
Pneumonia 
+* 
Pulmonary infundibular stenosis Pulmonary infundibular stenosis
+ +
+ +
 
2 y 2.5 mo
G-CSF; antibiotic prophylaxis IVIG
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October 2012 CLINICAL AND LABORATORY OBSERVATIONSendothelial biology and heart development—in particular,
ventricular septum and heart valve development.20,21 Its
germline deletion results in perinatal lethality, and its muta-
tion affects semilunar valve development, contributing to
aortic and pulmonary valve stenosis and, in some cases, sep-
tal defects.22 Recent findings support the view that CXCR7
modulates CXCR4 function by acting as a scavenger for
CXCL1223 and forming heterodimers with CXCR4.20,24,25
In vitro studies on endothelial progenitor cell function
show a role for both CXCR4 and CXCR7 in regulating the re-
sponse of the cells to CXCL12 and, thus, angiogenesis.21 This
suggests that interactions between the 2 chemokine receptors
may be required for proper valve morphogenesis.
Our observations demonstrate that TOF can be a present-
ing manifestation of WHIM syndrome and that this rare in-
herited disease should be suspected in children with
a congenital heart defect and neutropenia. The recognition
of this manifestation of WHIM syndrome might help to pre-
vent the diagnostic delay in the identification of this rare ge-
netic disease.
A prompt diagnosis should facilitate the management of
leucopenia, which might include in the future CXCR4-
targeted therapy as supported by 2 recent studies indicating
that the specific CXCR4 antagonist plerixafor may be effec-
tive in restoring the cellular blood counts to normal.26,27 n
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